Short-Term Changes in Intraocular Pressure After Intravitreal Injection of Bevacizumab for the Treatment of Retinopathy of Prematurity

Figures & data

Table 1 Baseline Characteristics of Patients

Patient No./ Sex/PMA(Weeks)	Weight at Birth (g)	Study Eye	Day of Injection	Axial Length (mm)	Depth of Anterior Chamber (mm)	Thickness of Lens (mm)
1/F/25w1d^a	428	L	36w2d	18.64	1.65	3.6
2/M/32w	1348	L	38w6d	18.05	2.57	3.97
3/M/26w	802	L	33w6d	19.01	1.79	3.99
4/M/25w1d	774	L	34w2d	19.25	1.82	4.12
5/M/25w1d	717	L	36w	19.71	1.91	4.37

Note: ^a25w1d (ie, 25 weeks plus 1 day).

Abbreviation: PMA, postmenstrual age.

Table 2 Intraocular Pressure (mmHg)

Patient No	Before IVB	1 min After IVB	3 mins After IVB	10 mins After IVB	30 mins After IVB	60 mins After IVB
1	6.3	23.9	18.4	16.5	12.8	9.6
2	9.4	20.3	12.8	6.4	5.8	10.0
3	11.5	16.4	7.6	7.6	6.2	6.9
4	6.0	19.9	17.4	13.3	8.6	7.3
5	6.6	18.3	16.7	12.0	13.2	7.4

Abbreviation: IVB, Intravitreal injection of bevacizumab.

Figure 1 Changes in intraocular pressure (IOP) after intravitreal injection of bevacizumab. Only the IOP at 1 min after injection was significantly different from that at baseline “pre”.